Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) i...

por Kalbakis, K, Kouroussis, Ch, Kakolyris, S, Mavroudis, D, Souglakos, J, Agelaki, S, Vamvakas, L, Christodoulakis, M, Stylianou, K, Georgoulias, V
Publicado 2001

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer

por Androulakis, N, Agelaki, S, Perraki, M, Apostolaki, S, Bozionelou, V, Pallis, A, Kalbakis, K, Xyrafas, A, Mavroudis, D, Georgoulias, V
Publicado 2012

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer

por Xenidis, N, Perraki, M, Apostolaki, S, Agelaki, S, Kalbakis, K, Vardakis, N, Kalykaki, A, Xyrafas, A, Kakolyris, S, Mavroudis, D, Georgoulias, V
Publicado 2013

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt,...

por Saridaki, Z, Androulakis, N, Vardakis, N, Vamvakas, L, Kabouraki, E, Kalbakis, K, Hatzidaki, D, Voutsina, A, Mavroudis, D, Georgoulias, V, Souglakos, J
Publicado 2012

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter random...

por Georgoulias, V, Agelidou, A, Syrigos, K, Rapti, A, Agelidou, M, Nikolakopoulos, J, Polyzos, A, Athanasiadis, A, Tselepatiotis, E, Androulakis, N, Kalbakis, K, Samonis, G, Mavroudis, D
Publicado 2005